References
- Wang Z, Cole PA. Catalytic mechanisms and regulation of protein kinases. Methods Enzymol. 2014;548:1–21.
- Manning G, Plowman GD, Hunter T, et al. Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci. 2002;27:514–520.
- Regad T. Targeting RTK signaling pathways in cancer. Cancers. 2015;7:1758–1784.
- Timothy J, Stuhlmiller SM, Miller JS, et al. Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains. Cell Reports. 2015;11(3):390–404.
- Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res. 2006;12:1398–1401.
- Schenone S, Manetti F, Botta M. SRC inhibitors and angiogenesis. Curr Pharm Des. 2007;13:2118–2128.
- Gocek E, Moulas AN, Studzinski GP. Non-receptor protein tyrosine kinases signaling pathways in normal and cancer cells. Crit Rev Clin Lab Sci. 2014;51:125–137.
- Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol. 2014;34:1722–1732.
- Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–5272.
- Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309(5967):418–425. DOI:https://doi.org/10.1038/309418a0.
- Alexandr P, Kornev N, Haste M, et al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci U S A. 2006;103(47):17783–17788.
- Suda K, Onozato R, Yatabe Y, et al. EGFR t790m mutation: a double role in lung cancer cell survival? J Thorac Oncol. 2009;4:1–4.
- Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007;11:217–227.
- Attili I, Karachaliou N, Conte P, et al. Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2018;18:1021–1030.
- Engel J, Richters A, Getlik M, et al. Targeting drug resistance in EGFR with covalent inhibitors: a structure-based Design approach. J Med Chem. 2015;58:6844–6863.
- Lu X, Yu L, Zhang Z, et al. Targeting EGFR L858R/T790M and EGFR L858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev. 2018;38:1550–1581.
- Toolabi M, Moghimi S, Oghabi M, et al. 6-Cinnamoyl-4-arylaminothienopyrimidines as highly potent cytotoxic agents: design, synthesis and structure-activity relationship studies. Eur J Med Chem. 2020;185:111786.
- Cortopassi WA, Feital RJC, Medeiros DdJ, et al. Docking and molecular dynamics studies of new potential inhibitors of the human epidermal receptor 2. Molecular Simulation. 2012;38(13):1132–1142. DOI: https://doi.org/10.1080/08927022.2012.696113.
- Cataldo VD, Gibbons DL, Pérez-Soler R. Quintás-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. New Engl J Med. 2011;364:947–955.
- Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015; 5: 390–401.
- Wang S, Cang S, Liu D. Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol. 2016;9:1–7.
- Cheng H, Nair SK, Murray BW. Recent progress on third generation covalent EGFR inhibitors. Bioorg. Med Chem Lett. 2016;26:1861–1868.
- Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Cancer. 2013; 119: 4325–4332.
- Kuiper JL, Heideman DA, Thunnissen E, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR mutated NSCLC-patients. Lung Cancer. 2014;85:19–24.
- Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides Insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010;70:868–874.
- Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol. 2012;83:407–421.
- Camidge DR, Pao W, Sequist LP. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473–481.
- Xu J, Wang J, Zhang S. Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget. 2017;8:90557–90578.
- Denis MG, Vallee A, Theoleyre S. EGFR t790m resistance mutation in non-small-cell lung carcinoma. Clin Chim Acta. 2015;444:81–85.
- Ward RA, Anderton MJ, Ashton S, et al. Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). J. Med. Chem. 2013;56:7025–7048.
- Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential Treatment strategy. Cells. 2018;7:1–16.
- Ayati A, Moghimi S, Salarinejad S, et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020: 103811, DOI:https://doi.org/10.1016/j.bioorg.2020.103811. Epub 2020 Apr 2. PMID: 32278207.
- Lemaitre V, Ali R, Kim CG, et al. Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation. FEBS Lett. 2004;563:75–81.
- Delhommelle J. Recent advances in molecular simulation. Molecular Simulation. 2011;37(7):515–515. DOI:https://doi.org/10.1080/08927022.2011.579409.
- Veronica S, Stefano M. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview. Front Pharmacol. 2018;9:923, DOI: https://doi.org/10.3389/fphar.2018.00923.
- Wong CF. Molecular simulation of drug-binding kinetics. Molecular Simulation. 2014;40(10–11):889–903. DOI: https://doi.org/10.1080/08927022.2014.890722.
- Olsson MH, Søndergaard CR, Rostkowski M, et al. PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput. 2011;87(2):525–537. DOI: https://doi.org/10.1021/ct100578z. Epub 2011 Jan 6. PMID: 26596171.
- Sastry GM, Adzhigirey M, Day T, et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013; 27: 221–234. DOI: https://doi.org/10.1007/s10822-013-9644-8.
- Shelley JC, Cholleti A, Frye LL, et al. Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 2007;21(12):681–691. DOI: https://doi.org/10.1007/s10822-007-9133-z. Epub 2007 Sep 27. PMID: 17899391.
- MacroModel, version 10.8, Glide, version 6.7, Schrödinger, LLC, New York (NY); 2015.
- Kevin J B, Chow E, Xu H, et al. Scalable algorithms for molecular dynamics simulations on commodity clusters, Proceedings of the ACM/IEEE Conference on Supercomputing (SC06), Tampa (FL); 2006; 11–17.
- Harder E, Damm W, Maple J, et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. J Chem Theory Comput. 2015. DOI: https://doi.org/10.1021/acs.jctc.5b00864
- Singh A & Mishra A. Leucoefdin a potential inhibitor against SARS CoV-2 mpro, J Biomol Struct Dyn. 2020. DOI: https://doi.org/10.1080/07391102.2020.1777903
- Prime, version 4.0, Schrödinger, LLC, New York (NY), 2015
- Jakubík J, Randáková A, Vladimír D. On homology modelling of the M2 muscarinic acetylcholine receptor subtype. J Comput Aided Mol Des. 2013;27(6):525–538. Doi: https://doi.org/10.1007/s10822-013-9660-8.
- Das D, Koh Y, Tojo Y, et al. Prediction of potency of protease inhibitors using free energy simulations with polarizable quantum mechanics-based ligand charges and a hybrid water model. J Chem Inf Mode. 2009;49:2851–2862.
- Li J, Abel R, Zhu K, et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modelling. Proteins: Struct Funct Genet.. 2011;79:2794–2812. DOI: https://doi.org/10.1002/prot.23106.
- Mulakala C, Viswanadhan VN. Could MM-GBSA be accurate enough for calculation of absolute protein/ligand binding free energies? J Mol Graph Model. 2013;46:41–51. DOI: https://doi.org/10.1016/j.jmgm.2013.09.005.
- Srivastava HK, Sastry GN. Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches. J Chem Inf Model. 2012;52:3088.
- Lipinski CA, et al.. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Deliv Rev. 1997;23(3):3–25.
- Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent Treatment strategies. Clin Cancer Res. 2015;21:3924–3933.
- Zhao P, Yao MY, Zhu SJ, et al. Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045. Biochem Biophys Res Commun. 2018;502:332–337. DOI: https://doi.org/10.1016/j.bbrc.2018.05.154.
- Spellmon N, Li C, Yang Z. Allosterically targeting EGFR drug-resistance gatekeeper mutations. J Thorac Dis. 2017;9(7):1756–1758. DOI: https://doi.org/10.21037/jtd.2017.06.43.
- Christ CD, Mark AE, van Gunsteren WF. Basic ingredients of free energy calculations: a review. J Comput Chem. 2009;31:1569–1582.
- Gohlke H, Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Ang Chem Int Ed. 2002;41:2644–2676.
- Gohlke H, Kiel C, Case DA. Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RaI GDS complexes. J Mol Biol. 2003;330(4):891–913.
- Kollman PA, Massova I, Reyes C, Kuhn B, Huo SH. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000; 33 (12): 889–897.
- Wang JM, Hou TJ, Xu XJ. Recent advances in free energy calculations with a combination of molecular mechanics and continuum models. Curr Comput-Aided Drug Des. 2006;2(3):287–306.
- Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51:817–834. DOI: https://doi.org/10.1021/jm701122q.
- Selick HE, Beresford AP, Tarbit MH. The emerging impotance of predictive ADME simulation in drug discovery. Drug Dicovery Today. 2002;2:109–116.
- Yamashita S, Furubayashi T, Kataoka M, et al. Optimized conditions for prediction of intestinal drug permeability using caco-2 cells. Eur J Pharm Sci. 2000;10(3):195–204. DOI: https://doi.org/10.1016/s0928-0987(00)00076-2. PMID: 10767597.
- Irvine JD, Takahashi L, Lockhart K, et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci. 1999;88(1):28–33. DOI: https://doi.org/10.1021/js9803205. PMID: 9874698.
- Singh S, Singh J. Transdermal drug delivery by passive diffusion and iontophoresis: a review. Med Res Rev. 1993;13(5):569–621. DOI: https://doi.org/10.1002/med.2610130504. PMID: 8412408.